Bli medlem
Bli medlem

Du är här


Meridian Bioscience, Inc.: New Malaria Test, illumigene® Malaria, Sets a New Gold Standard for Diagnosis

Meridian Bioscience Collaborates With the Centers for Disease Control and Prevention and Cheikh Anta Diop University of Dakar to Launch Diagnostic Test up to 80,000 Times More Sensitive Than Current OptionsCINCINNATI, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.
(NASDAQ:VIVO) today announced that it has received the CE Mark for illumi


Malaria, a novel, highly accurate test developed by Meridian with the
technical assistance of the Centers for Disease Control and Prevention (CDC)
and Cheikh Anta Diop University of Dakar, Senegal. The test is up to 80,000
times more sensitive at detecting the malaria parasite than conventional
tests, potentially revolutionizing malaria diagnosis and establishing a new
gold standard. Using innovative molecular LAMP technology, illumi


results are available in under one hour, and the test is easy to use as it
does not rely on high level technical expertise. This is a major step forward
for people with malaria as faster, more accurate diagnoses should lead to
prompt treatment and better outcomes. illumi


Malaria will be distributed in the European, Middle Eastern and African
regions by Meridian Bioscience Europe and in additional international markets
by the Company's global distribution network.

Despite a 60% decline in malaria deaths since 2000, because of better
prevention and increased control measures, malaria is still one of the top
three killers of children worldwide claiming one life every minute of every
day. Malaria is no longer only a disease of sub-Saharan Africa and southern
Asia. Increasing numbers of people emigrating from countries where malaria is
endemic have resulted in a higher incidence in Europe and the Middle East.
The proportion of imported malaria cases has increased during the last few
years from 14% to 86% in more recent studies. On pooling the reports, nearly
43% of malaria cases registered in key European centers occurred in
non-nationals. The rates of malaria are much higher in settled immigrants who
travel to visit friends and relatives (VFRs) in their country of origin. They
can account for up to 70% of the cases in several reports and this increase
highlights the need for better diagnostic tools in both non-endemic and
endemic countries.



Malaria has the potential to change current practices. Faster and more
accurate diagnosis is vital in the fight against malaria. Earlier diagnosis
enables the correct treatment to be prescribed which leads to better clinical
outcomes for the person with malaria and keeps malaria treatments for the
right people. Because of submicroscopic parasitemia carriage among the
populations, a robust, sensitive and field community-deployable screening
tool is needed to track the malaria reservoir in pre-elimination regions.

gene Malaria shows this capacity," said Professor Daouda NDIAYE, Department of
Parasitology-Mycology, Cheikh Anta Diop University of Dakar, Senegal.

Meridian Bioscience has worked actively with leading experts at the CDC and
the Cheikh Anta Diop University of Dakar during the development of illumi

gene Malaria and collaborated with these organizations to design clinical
trials. Data from over 200 patients from Senegal validated the performance of


Malaria. The test demonstrated 100% sensitivity, but more importantly, it
also detected infected patients that were missed by conventional methods for
the identification of Malaria.

"Patient care is central to Meridian's work and we consider the needs of all
those involved in diagnosis when developing our products. Malaria remains one
of the most dangerous diseases in the world both in endemic and increasingly
non-endemic countries. illumi


Malaria delivers a high level of sensitivity combined with a quick turnaround
time and simple procedure, a combination of attributes that have been lacking
in this disease area. Malaria is the tenth assay now available on our illumi


platform that is in use in nearly 1,500 institutions around the world. We
are proud to be able to join the fight against Malaria with our flagship


molecular technology." said Mike Shaughnessy, Executive Vice President and
President of Meridian Global Diagnostics.

Notes to Editors:

About Professor Daouda Ndiaye

, PharmD, MsC, PhD

* Professor Ndiaye is Professor of Parasitology and Mycology and Director of
the Senegal African Centre for Excellence on Genomic and Infectious
Diseases, based at the University Cheikh Anta Diop, Senegal
* Professor Ndiaye gained his PhD from Harvard University and is currently a
visiting scientist at the Harvard TH Chan School of Public Health,
Department of Immunology and Infectious Diseases
* Professor Daouda Ndiaye will be available for interview upon request.


gene® Malaria&LAMP Technology

* illumi gene Malaria is a diagnostic test for malaria developed by Meridian
Bioscience. It is a molecular test that uses Loop-Mediated Isothermal
Amplification (LAMP) technology to amplify DNA and detect the presence of
the Malaria parasite
* LAMP technology is isothermal and so can be used at room temperature
without the need to heat reagents or the material being tested, unlike the
rapid diagnostic tests currently used in Malaria which use polymerase chain
reaction (PCR) technology. illumi gene Malaria does not require
* Illumigene technology is simple, accurate and easy to use which means that
no specialist technical expertise is needed to use the test. Results are
available in under an hour.
* LAMP based illumi gene tests are already used to diagnose infectious
diseases including C. difficile, whooping cough and Herpes Simplex Virus,
where they have proved highly accurate.
* Illumi gene tests have been approved and used in other diseases for over 5

About Meridian Bioscience, Inc

Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative diagnostic
test kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and speed in
the early diagnosis and treatment of common medical conditions, such as
gastrointestinal, viral and respiratory infections. Meridian's diagnostic
products are used outside of the human body and require little or no special
equipment. The Company's products are designed to enhance patient well-being
while reducing the total outcome costs of healthcare. Meridian has strong
market positions in the areas of gastrointestinal and upper respiratory
infections, serology, parasitology and fungal disease diagnosis. In addition,
Meridian is a supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for new
drugs and vaccines. The Company markets its products and technologies to
hospitals, reference laboratories, research centers, diagnostics
manufacturers and biotech companies in more than 70 countries around the
world. The Company's shares are traded on NASDAQ's Global Select Market,
symbol VIVO. Meridian's website address is

For news coverage on product information regarding

gene® Malaria including interview requests and images (photography of
Professor Ndiaye's Senegal clinic is available) please contact:

* For UK and pan-European: Sarah Herbert, on +44
203 219 8708
* For France: Barbara Joly - on +33 6 61 19 97 96
* For Spain: Lucia Sixto - on +34 93 635 05 00
* For Italy: Antonella Di-Fatta -
on +39 33 47 15 13 18
* For Saudi Arabia: Nahed Ashour - on
+971 50 820 8100
Contact: 513.271.3700

John A. Kraeutler, Chief Executive Officer


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meridian Bioscience, Inc. via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.